Thursday, November 12, 2026

Platinum Futures Is 13% Down In The Last 21 Sessions

Platinum Futures Is 13% Down In The Last 21 Sessions

(VIANEWS) - Platinum (PL) has been up by 13.38% for the last 21 sessions. At 11:50 EST on Thursday, 29 June, Platinum (PL) is $902.80.

Volume

Today's last reported volume for Platinum is 22998, 99.99% below its average volume of 9851175311.35.

Volatility

Platinum's last week, last month's, and last quarter's current intraday variation average was a negative 0.24%, a negative 0.70%, and a positive 1.31%, respectively.

Platinum's highest amplitude of average volatility was 0.30% (last week), 1.00% (last month), and 1.31% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Platinum's commodity is considered to be overbought (>=80).

News about

  • WTI crude oil forecast: traders using range-bound strategies as market consolidates - 28 June 2023. According to DailyForex on Wednesday, 28 June, "The WTI Crude Oil and Brent Crude markets remain range-bound, displaying a consolidation pattern that aligns with the summer season's typically subdued trading activity. ", "WTI Crude Oil is projected to be between $65 and $75, while Brent Crude's range is expected to fluctuate between approximately $70 and $80. "
  • According to FXStreet on Tuesday, 27 June, "For the rest of the session, the American Petroleum Institute will release Crude Oil Stocks for the week ending on June 23, which could have an additional impact on the black gold's price dynamics."

More news about Platinum (PL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com